|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 61.94 CNY | -1.95% |
|
-2.88% | +3.98% |
| Jan. 12 | Hengrui Pharma Unit Secures Approval to Conduct Clinical Trial for Hypertension Drug | MT |
| Jan. 12 | Hengrui Pharma's Cancer Drug Obtains China Breakthrough Therapy Designation | MT |
Business description: Jiangsu Hengrui Pharmaceuticals Co.,Ltd
- anti-tumor drugs (No. 1 Chinese);
- Anesthetic drugs;
- contrast agents: used in medical imaging;
- anti-inflammatory drugs;
- drugs for the treatment of cardiovascular diseases.
Number of employees: 20,238
Sales by Activity: Jiangsu Hengrui Pharmaceuticals Co.,Ltd
| Fiscal Period: December | 2020 (CNY) | 2021 (CNY) | 2022 (CNY) | 2023 (CNY) | 2024 (CNY) |
|---|---|---|---|---|---|
Medicine Manufacturing | 27.73B | 25.91B | 21.28B | 22.82B | 27.98B |
Geographical breakdown of sales: Jiangsu Hengrui Pharmaceuticals Co.,Ltd
| Fiscal Period: December | 2020 (CNY) | 2021 (CNY) | 2022 (CNY) | 2023 (CNY) | 2024 (CNY) |
|---|---|---|---|---|---|
China | 26.85B | 25.16B | 20.43B | 21.76B | 24.29B |
Foreign | 758M | 617M | 779M | 617M | 716M |
Executive Committee: Jiangsu Hengrui Pharmaceuticals Co.,Ltd
| Manager | Title | Age | Since |
|---|---|---|---|
Jian Jun Liu
DFI | Director of Finance/CFO | 49 | 2021-11-18 |
Ji Feng
PSD | President | - | 2025-04-01 |
Yu Xu
CMP | Compliance Officer | 34 | 2021-05-31 |
Ning Jun Jiang
PRN | Corporate Officer/Principal | 65 | 2023-02-01 |
Lian Shan Zhang
PRN | Corporate Officer/Principal | 65 | 2010-08-05 |
Composition of the Board of Directors: Jiangsu Hengrui Pharmaceuticals Co.,Ltd
| Director | Title | Age | Since |
|---|---|---|---|
Jie Ping Sun
BRD | Director/Board Member | 56 | 2020-01-15 |
Hong Bin Dai
BRD | Director/Board Member | 50 | 2020-01-15 |
Piao Yang Sun
CHM | Chairman | 67 | 2021-07-07 |
Lian Shan Zhang
BRD | Director/Board Member | 65 | 2012-04-10 |
Guo Qiang Xiong
BRD | Director/Board Member | 51 | 2004-12-31 |
Cong Zhao Guo
BRD | Director/Board Member | 54 | 2020-01-15 |
Jia Hong Dong
BRD | Director/Board Member | 66 | 2021-05-10 |
Yu Xu
BRD | Director/Board Member | 34 | 2022-07-07 |
Ning Jun Jiang
BRD | Director/Board Member | 65 | 2023-02-01 |
Qing Sheng Zeng
BRD | Director/Board Member | 51 | 2023-02-01 |
Company details: Jiangsu Hengrui Pharmaceuticals Co.,Ltd
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
7 Kunlunshan Road
222000, Lianyungang
+
http://www.hengrui.com
Other Pharmaceuticals
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.95% | -2.88% | +44.58% | +46.85% | 59.15B | |
| +0.53% | -2.37% | +43.09% | +190.27% | 930B | |
| -0.41% | +6.98% | +48.72% | +26.86% | 527B | |
| -0.31% | -2.60% | +24.94% | +40.25% | 379B | |
| +0.93% | +2.38% | +31.46% | +18.47% | 371B | |
| +0.19% | -1.15% | +28.47% | +21.14% | 292B | |
| -1.93% | -1.54% | +11.14% | -1.47% | 270B | |
| +0.98% | +1.37% | +29.42% | +35.03% | 276B | |
| +6.49% | +1.95% | -35.37% | -18.36% | 268B | |
| +0.12% | +1.32% | +21.43% | +22.64% | 178B | |
| Average | +0.46% | +0.34% | +24.79% | +38.17% | 355.01B | |
| Weighted average by Cap. | +0.55% | +0.45% | +29.09% | +64.92% |
Sector
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- 600276 Stock
- Company Jiangsu Hengrui Pharmaceuticals Co.,Ltd
Select your edition
All financial news and data tailored to specific country editions
